I was recently watching BioIDEA’s Biotech vs COVID-19 event. During the event our CEO, Andrew Satz, was asked about the viability of fully computational drug discovery and development. His answer surprised me. He discussed a number of legitimate hurdles that need to...
Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies' "Alumni in Action." The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term...
NEW YORK, NY and SOUTH SAN FRANCISCO, Calif – July 2, 2020 -- EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling...
https://youtu.be/qIW1o8jgRsk Our technology works by taking an antibody sequence of interest and performing evolutionary modeled mutagenesis, mimicking the natural selection inherent to antibody VDJ recombination and affinity maturation. Using large amounts of public...
EVQLV's CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more. Give it a listen below. https://youtu.be/A2QoFVnD1Wc Timestamps: Andrew's...
Our CEO was recently asked how far away is fully computational drug discovery and development. This isn't an easy question to answer and Andrew doesn't provide an exact date. However, he does provide interesting insight into the progress we've made and the challenges...
We recently held an event with BioIDEA: Biotech vs COVID-19. During the event, our CEO, Andrew Satz, was asked the value of computational drug discovery beyond just speed. Andrew explained that while speed is important, it can also be dangerous, and is certainly not...
This is a clip from our event with BioIDEA: Biotech vs COVID-19. Our CEO, Andrew Satz, explains how our technology works, with specific attention to our work on COVID-19. Give it a listen below (transcription beneath video). Transcription: We use nearly a hundred...
EVQLV's very own Andrew Satz (CEO and CO-Founder) was a guest on the M2 Techcast of MITechNews.com with Mike Brennan and Matt Roush. He discussed our work on coronavirus, what is and isn't artificial intelligence, the application of AI, and our mission at EVQLV. Give...
Below is a clip from Andrew Satz's (CEO, EVQLV) speech at the Flatiron School. He explains what we do at EVQLV and how we do it. In short, we use artificial intelligence (AI) to discover and optimize novel biologics. Our algorithm uses an evolutionary approach with...